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Abstract  
Influenza viruses are major respiratory pathogens responsible for both seasonal epidemics and 
occasional pandemics worldwide. The current available treatment options have limited efficacy and 
thus the development of new antivirals is highly needed. We previously reported the identification 
of a series of cycloheptathiophene-3-carboxamide compounds as influenza A virus inhibitors that 
act by targeting the protein-protein interactions between the PA-PB1 subunits of the viral 
polymerase. In this study, we characterized the antiviral properties of the most promising 
compounds as well as investigated their propensity to induce drug resistance. Our results show that 
some of the selected compounds possess potent, broad-spectrum anti-influenza activity as they 
efficiently inhibited the replication of several strains of influenza A and B viruses, including an 
oseltamivir-resistant clinical isolate, with nanomolar or low-micromolar potency. The most 
promising compounds specifically inhibited the PA−PB1 binding in vitro and interfered with the 
influenza A virus polymerase activity in a cellular context, without showing cytotoxicity. The most 
active PA-PB1 inhibitors showed to possess a drug resistance barrier higher than that of oseltamivir. 
Indeed, no viral variants with reduced susceptibility to the selected compounds emerged after serial 
passages of influenza A virus under drug selective pressure. Overall, our studies identified potent 
PA-PB1 inhibitors as promising candidates for the development of new anti-influenza drugs. 
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1. Introduction 
Influenza A viruses (IAV) are pathogens that infect a variety of bird and mammalian hosts and 
along with influenza B viruses cause seasonal epidemics of influenza, a contagious respiratory 
disease, in humans. According to the World Health Organization (WHO), the global burden of 
seasonal influenza is estimated to be on the order of 3–5 million cases of severe illness annually 
resulting in 300,000–650,000 deaths (WHO, 2018), especially among people at high risk of 
developing influenza-related complications (e.g., the elderly, immunocompromised individuals, and 
patients with underlying chronic respiratory and cardiovascular diseases). IAV is also responsible 
for recurring human pandemics, which in the past caused devastating effects on the global 
population in terms of prevalence and mortality rates (Taubenberger and Kash, 2010). In addition, 
in recent years some subtypes of avian IAV (e.g., H5N1, H7N9) have crossed the species barrier 
and caused thousands of documented zoonotic outbreaks in humans, leading to severe disease 
associated with high mortality (Gao et al., 2013; Lai et al., 2016). Although there is no current 
evidence of a sustained human-to-human spread of these avian influenza virus strains, their 
pandemic potential is clear and poses a serious and constant threat to global public health. 
Vaccination is the main strategy to prevent influenza infections, but current available 
vaccines fail to provide cross-protection against all subtypes of influenza virus and have several 
other limitations. Indeed, due to high mutation rates of influenza virus that lead to viral antigenic 
variability, anti-influenza vaccines must be reformulated on an annual basis and a good antigenic 
match between circulating strains and vaccine composition is difficult to attain (Salzberg, 2008). 
Moreover, vaccines have low efficacy in high-risk groups and the lag time needed to produce a new 
vaccine may not be able to control a potential rapid spread of pandemic strains. For these reasons, 
antiviral drugs are clearly needed for the management of influenza infections. Since M2 blockers 
(i.e., amantadine and rimantadine) are no longer recommended in clinical setting due to the 
widespread circulation of drug-resistant viruses (Loregian et al., 2014; Dong et al., 2015), currently 
the first-line drugs for the prophylaxis and the treatment of IAV and IBV infections are the 
neuraminidase (NA) inhibitors, represented by oseltamivir (OST), zanamivir, and peramivir 
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(Gubareva et al., 2000; Loregian et al., 2014). However, the emergence and spread of drug-resistant 
IAV strains have been also reported for NA inhibitors, thus limiting their clinical effectiveness 
(Moscona, 2009; Li et al., 2015). Considering this concern, the development of anti-influenza drugs 
with different mechanisms of action is highly required. 
IAV and IBV RNA-dependent RNA polymerase (RdRP) is a heterotrimeric complex 
composed of polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase 
acidic protein (PA) subunits. RdRP has a pivotal role in virus replication, as it is responsible for 
both viral transcription and replication (Fodor, 2013). Due to its multiple and essential enzymatic 
activities, RdRP represents a promising target for the development of anti-influenza drugs with 
alternative mechanisms of action (Loregian et al., 2014; Stevaert and Naesens, 2016). Many 
inhibitors targeting different components and functions of the RdRP have been developed and three 
of them have been recently approved for clinical use or are in late-phase clinical trials (Koszalka et 
al., 2017). These compounds are: i) favipiravir (formerly known as T-705), a purine nucleoside 
analogue; ii) pimodivir (also known as VX-787 or JNJ63623872), a cap-binding inhibitor of the 
PB2 subunit; and iii) baloxavir marboxil (known as S-033188, the prodrug of S-033447), an 
enzymatic inhibitor of PA endonuclease. Baloxavir marboxil has been recently approved in US and 
in Japan for the treatment of IAV and IBV infections (Hayden and Shindo 2019), while favipiravir 
has been licensed as anti-influenza drug in Japan (Koszalka et al., 2017). 
An appealing approach to selectively inhibit RdRP functions is to interfere with proper 
complex formation. The assembly of the three subunits into a functional trimeric complex is 
required for the RdRP to exert its functions (Toyoda et al., 1996; Gonzàlez et., 1996; Perez and 
Donis, 2001). Structural studies have revealed inter-subunit interactions between the C-terminal 
portion of PA and the N-terminus of PB1 (He et al., 2008; Obayashi et al., 2008, Pflug et al., 2014) 
as well as between the C-terminal domain of PB1 and the N-terminus of PB2 (Sugiyama et al., 
2009; Pflug et al., 2014). Since these interactions are essential for viral replication and their binding 
interfaces are highly conserved among IAV and IBV strains (Pérez and Donis, 1995; Ghanem et al., 
2007; Stevaert and Naesens, 2016), the disruption of such interactions represents an attractive 
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strategy for the development of anti-influenza drugs with broad activity (Loregian et al., 2002; 
Loregian and Palù, 2005; Palù and Loregian, 2013; Loregian et al., 2014; Stevaert and Naesens, 
2016; Massari et al., 2016). The feasibility and the effectiveness of such an approach have been 
demonstrated by the increasing number of PA-PB1 dissociative inhibitors developed in the last 
decade (Wunderlich et al., 2009; Wunderlich et al., 2011; Muratore et al., 2012a; Muratore et al., 
2012b; Fukuoka et al., 2012; Massari et al., 2013; Kessler et al., 2013; Lepri et al., 2014; Pagano et 
al., 2014; Tintori et al., 2014; Massari et al., 2015; Trist et al., 2016; Yuan et al., 2016; Desantis et 
al., 2017; Watanabe et al., 2017; Massari et al., 2017; Zhang et al., 2018; D’Agostino et al., 2018). 
Among these, we recently reported the discovery of compounds with a cycloheptathiophene-3-
carboxamide (cHTC) scaffold as PA-PB1 inhibitors (Desantis et al., 2017). In preliminary studies, 
we identified a series of cHTC derivatives able both to disrupt the binding between PA and PB1 in 
vitro as well as to inhibit the replication of IAV A/Puerto Rico/8/1934 (PR/8 strain) in infected cells 
(Desantis et al., 2017).  
In this study, we  further characterized the antiviral activity of the most promising cHTC 
derivatives and assessed their potential to develop drug resistance. Some of the tested cHTC 
compounds exhibited potent, broad anti-influenza activity and showed to act by interfering 
specifically with the correct assembly and activity of influenza virus RdRP. Most importantly, we 
were not able to isolate a viral variant resistant to three different cHTC PA-PB1 inhibitors. Overall, 
our studies demonstrated cHTC compounds as promising antivirals against IAV and IBV infections. 
 
2. Materials & Methods 
 
2.1. Compounds and peptide 
Compounds 21, 29, 31, 32, 37, and 54 were synthesized as previously described (Desantis et al., 
2017; Desantis et al., 2018). Each test compound was dissolved in dimethyl sulfoxide (DMSO). 
Ribavirin (RBV, 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) and oseltamivir carboxylic acid 
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(OST) were purchased from Roche; favipiravir (T-705, 6-fluoro-3-hydroxy-2-
pyrazinecarboxamide) was purchased from Selleck Chemicals. The PB1(1–15)–Tat peptide was 
obtained by the Peptide Facility of CRIBI Biotechnology Center (University of Padua, Padua, 
Italy). This peptide comprises the 15 N-terminal residues of the PB1, i.e. the PA-interacting portion 
of the protein, conjugated to the amino acid sequence of HIV Tat protein (residues 47−59). RBV, 
OST, and PB1(1–15)–Tat peptide were dissolved in water. 
 
2.2. Cells and virus 
Mardin-Darby canine kidney (MDCK) and human embryonic kidney (HEK) 293T cells were 
routinely grown in Dulbecco’s modified Eagle’s medium (DMEM, Life Biotechnologies) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Life Technologies) and 
antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin sulfate, Life Technologies) at 
37°C with 5% CO2. Influenza A/Puerto Rico/8/1934 (PR/8, H1N1, Cambridge lineage) was kindly 
provided by P. Digard (Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom). 
Influenza virus strains A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), 
B/Malaysia/2506/2004 (Victoria lineage), and B/Bangladesh/333/2007 (Yamagata lineage) were 
provided by R. Cusinato (Clinical Microbiology and Virology Unit, Padua University Hospital, 
Padua, Italy). Influenza B/Lee/1940 virus (B/Lee, ancestral lineage) was obtained from W. S. 
Barclay (Imperial College, London, United Kingdom). The clinical isolate A/Parma/24/2009 
(H1N1, OST-resistant) was kindly provided by I. Donatelli (Istituto Superiore di Sanità, Rome, 
Italy), while a local strain of the 2009 pandemic variant H1N1 IAV, A/Padova/30/2011, was 
provided by C. Salata and A. Calistri (University of Padua, Padua, Italy).  
 
2.3. Plasmids 
The pD15-GST, pD15–PB11–25, and pET28a–PA239–716 plasmids, which encode glutathione S-
transferase (GST), GST-PB1(1−25), and 6His-PA(239−716) proteins, respectively, were generated as 
described elsewhere (Loregian et al., 2004; Muratore et al., 2012a). Plasmids pcDNA-PB2, pcDNA-
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PB1, pcDNA-PA, and pcDNA-NP, containing cDNA copies of the genomic segments 1, 2, 3, and 5 
of the IAV PR/8 strain for the expression of PB2, PB1, PA, and NP proteins, respectively, were 
kindly provided by P. Digard (Roslin Institute, University of Edinburgh, Edinburgh, United 
Kingdom). These plasmids were created as previously reported (Mullin et al., 2004). Reporter 
plasmid pPolIFlu-ffLuc containing an influenza virus-based luciferase minireplicon vRNA under 
the control of the human RNA polymerase I promoter was provided by L. Tiley (University of 
Cambridge, Cambridge, United Kingdom). Plasmid pRL-SV40 carrying Renilla luciferase reporter 
gene under the control of the constitutive early SV40 enhancer/promoter region was purchased from 
Promega. 
 
2.4. Protein expression and purification 
6His-PA(239−716), GST, and GST-PB1(1−25) proteins were expressed into E. coli strain 
BL21(DE3)pLysS (Stratagene) and purified as published previously (Loregian et al., 2004; 
Muratore et al., 2012a). 
 
2.5. PA-PB1 interaction enzyme-linked immunosorbent assay (ELISA)  
The PA−PB1 interaction was detected by a procedure previously described (Muratore et al., 2012a), 
with some modifications. Briefly, 96-well microtiter plates (Nuova Aptca) were coated with 400 ng 
per well of 6His-PA(239−716) and incubated at 37°C for 3 h. Coated wells were then blocked with 2% 
BSA (Sigma-Aldrich) in PBS for 1 h at 37°C. After 5 washes with PBS containing 0.3% Tween 20 
(Sigma-Aldrich), different concentrations of test compounds or DMSO, as a control, were dissolved 
in serum-free DMEM and added to the plates along with 200 ng of GST-PB1(1−25), or of GST alone 
as a background control. Each compound concentration was tested at least in duplicate. Plates were 
then incubated overnight at room temperature. After 5 washes with 0.3% Tween/PBS, the PA-PB1 
interaction was detected with a monoclonal anti-GST antibody conjugated to horseradish 
peroxidase (GenScript) diluted 1:4,000 in PBS plus 2% FBS. After the final washes, the peroxidase 
8 
 
substrate 3,3′,5,5′tetramethylbenzidine (TMB, KPL) was added to each well and absorbance was 
read at 450 nm by an ELISA plate reader (Tecan Sunrise™).  
 
2.6. Cytotoxicity assay 
Cytotoxicity of test and reference compounds was tested in HEK 293T and MDCK cells by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich) method. 
Briefly, HEK 293T or MDCK cells seeded in 96-well plates at 3×104 per well or 2×104 per well, 
respectively, were incubated at 37°C for 24 or 48 h, respectively, in the presence of compounds 
serially diluted in DMEM supplemented with 10% FBS and antibiotics. Cell viability was then 
determined as previously described (Loregian and Coen, 2006). 
 
2.7. Plaque reduction assays  
Plaque reduction assays (PRAs) with IAV and IBV were carried out as previously reported 
(Muratore et al., 2012a), with a few modifications. Briefly, confluent monolayers of MDCK cells in 
12-well plates were first washed with serum-free DMEM and then infected with 30-40 Plaque 
Forming Units (PFU) per well of influenza virus in DMEM supplemented with 2 μg/mL of L-1-
tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Worthington Biochemical 
Corporation) and 0.14% BSA, in the presence of different concentrations of test compounds or 
solvent (DMSO) as a control. After 1 h of incubation at 37°C, cells were incubated with medium 
containing 1.2% Avicel microcrystalline cellulose (FMC BioPolymer), 2 μg/mL of TPCK-treated 
trypsin, 0.14% BSA, and DMSO or test compounds. At 48 h post-infection (p.i.) for IAV and 48-72 
h p.i. for IBV, cell monolayers were fixed with 4% formaldehyde solution and stained with 0.1% 
toluidine blue.  
 
2.8. Virus yield reduction assay 
Virus yield reduction assay (VYRA) was performed as previously described (Muratore et al., 
2012a), with some modifications. MDCK cells (2×104 per well) were seeded into 96-well plates and 
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incubated overnight at 37°C. Cells were then infected with the IAV PR/8 strain at a multiplicity of 
infection (MOI) of 0.001 in DMEM plus 0.14% BSA and 1 μg/mL TPCK-treated trypsin for 1 h at 
37°C in the presence of various concentrations of test compounds or RBV as a control.. After 1 h, 
media were supplemented with fresh DMEM containing 2 µg/ml of TPCK-treated trypsin, 0.14% 
BSA, and compounds at the same concentrations. The culture supernatants were collected at 24 h 
p.i. and viral progeny was titrated by plaque assays in fresh MDCK cells. 
 
2.9. Minireplicon assay 
The minireplicon assay was performed as described elsewhere (Muratore et al., 2012a). HEK 293T 
cells (2×105 per well) were plated into 24-well plates and incubated overnight at 37°C. The 
following day, cells were transfected using calcium phosphate co-precipitation method with 
pcDNA-PB1, pcDNA-PB2, pcDNA-PA, pcDNA-NP plasmids (100 ng/well of each) along with 50 
ng/well of the pPolI-Flu-ffLuc reporter plasmid and 50 ng/well of pRL-SV40 plasmid as a 
transfection control. Transfections were performed in the presence of different concentrations of 
test compounds or DMSO, in duplicate. Cell medium was replaced 4 h post-transfection with 
DMEM supplemented with 10% FBS and the respective compound concentration or DMSO. At 24 
h post-transfection, cells were harvested, lysed and both firefly and Renilla luciferase activity were 
measured using the Dual Luciferase Assay Kit (Promega). In each experiment, firefly luciferase 
activity was normalized with that of the Renilla luciferase and relative luciferase units (RLU) were 
obtained.  
 
2.10. In vitro serial influenza virus passage experiments 
To evaluate the barrier to drug resistance of selected cHTC compounds (29, 31, and 54) and OST as 
a reference compound, IAV PR/8 strain was serially passaged in the presence of increasing 
concentrations of test compounds following a procedure previously described (Zhang et al., 2018). 
Briefly, confluent MDCK cells were infected with PR/8 at an MOI of 0.001 and then treated with 
test compounds or DMSO as a control. Cell supernatants were harvested when cytopathic effects 
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(CPEs) were evident, and the viral progenies titrated by plaque assay. The concentrations of PA-
PB1 inhibitors or OST applied to the first passage (P1) corresponded approximately to those of their 
respective EC50 values in PRAs (Table 1); successively, compound concentrations were 
systematically two-fold increased at each passage until the 6th passage (P6) and then kept constant 
(32-fold the initial concentration) for four additional passages for OST and for fourteen passages for 
all tested cHTC compounds (Table S3). For compound 54, at P21 compound concentration was 
further increased up to 100-fold the initial concentration and then kept constant for nine additional 
passages (until P30, Table S4). At selected passages, the drug sensitivity of harvested viruses was 
determined by PRA as described above, using parental PR/8 virus as a control.  
 
2.11. Statistical analysis  
Statistical analysis was carried out using GraphPad Prism version 7.0 (GraphPad Software, San 
Diego, CA, USA). Data are presented as the means ± standard deviations (SD) of at least two 
experiments in duplicate. The IC50, EC50 and CC50 values for the different assays were determined 
by nonlinear regression curve fitting (inhibitor versus normalized response with variable slope 
equation) using GraphPad Prism 7.0 software. 
 
3. Results  
 
3.1. Potent and broad-spectrum anti-influenza activity of selected cHTC compounds 
We previously identified a series of cHTC derivatives as PA-PB1 inhibitors able to inhibit IAV 
replication without showing significant toxicity in MDCK cells (Desantis et al., 2017). Among 
them, the most promising derivatives, i.e., 21, 29, 31, 32, 37, and 54, which were previously shown 
to inhibit the replication of IAV PR/8 in PRA with EC50 values <10 µM and with a selectivity index 
(SI) >25 (Desantis et al., 2017), were selected for further biological characterization. All of them 
are characterized by a cycloheptathiophene scaffold variously functionalized at the C-2 and C-3 
carboxamide moieties (Figure S1). In particular, compounds 21, 29, 31, and 32 bear an o-
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hydroxyphenyl moiety at the C-2 position coupled with various C-3 aromatic rings, i.e., 2-pyridine 
(21), p-chlorophenyl (29), p-fluorophenyl (31), and thiazol-2-yl (32). In compound 37, the o-
hydroxy moiety was moved to C-3 position coupled with a 2-pyridine ring at the C-2, while 
compound 54 presents the 2-pyridine ring at the C-3 position with a p-nitrophenyl ring as C-2 
substituent. To evaluate the spectrum of their anti-influenza activity, these compounds were tested 
by PRA against a panel of IAV strains, belonging to different co-circulating subtypes (i.e., H3N2 
and H1N1), as well as against different IBV strains, corresponding to the two distinct lineages 
(Yamagata and Victoria). RBV and OST were included as positive controls. Results showed that 
each anti-PA-PB1 compound inhibited all tested IAV and IBV strains with similar potency (Table 
1). As reported in Table 1, for compounds 29, 31, 32, and 54 EC50s were within the nanomolar 
range, while those of compounds 21 and 37 fell in the low-micromolar range. In particular, 54 
emerged as the most potent compound, with EC50s ranging from 0.08 to 0.27 µM. Of note, the 
selected cHTC compounds were found to be also active against a clinical isolate resistant to OST 
(A/Parma/24/2009 strain), with EC50 values comparable to those exhibited against the other tested 
viral strains. A dose-dependent activity was observed for all compounds against both IAV and IBV 
(Figure 1A) and EC90 values were in the sub-/low-micromolar range for all compounds except 37 
(Table S1). Moreover, treatment with compounds 21, 29, 31, 32, and 54 also resulted in the 
reduction of plaques size (Figure 1B). In conclusion, some of the selected cHTC compounds 
showed potent, broad-spectrum anti-influenza activity, providing cross-protection against the two 
different lineages of IBV and the currently circulating subtypes of human IAV. 
 
3.2. cHTC compounds treatment causes a dose-dependent reduction of infectious viral progeny 
To further characterize the anti-influenza activity of the compounds, we assessed the effects of 
various concentrations of each test compound, and RBV as a control, on the production of 
infectious progeny. At 24 h p.i., supernatants of infected cell cultures were harvested and titrated by 
plaque assays. A dose-dependent reduction of the viral progeny was observed with all test 
compounds ( Figure 2). Compounds 21, 29, 31, 32, and 54 exhibited EC50 values in the low-
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micromolar range (Table S2). A concentration-dependent reduction of viral progeny titres was also 
obtained with compound 37 but with higher EC50 values (13.2 µM, Table S2). For most 
compounds, EC50 values in VYRA were higher than those obtained in PRA, which might be due to 
the different MOIs used in the two experimental settings (i.e., ~ 0.00005 in PRA versus 0.001 in 
VYRA), arguing that due to the competitive mechanism of the PA-PB1 inhibitors, at least for some 
compounds the antiviral activity might be MOI-dependent.  
 
3.3 cHTC compounds specifically disrupt the PA–PB1 interaction in vitro in a dose-dependent 
manner 
The compounds under investigation were previously found to be able to disrupt the physical 
interaction between the PA and PB1 subunits of IAV RdRP in an ELISA-based interaction assay 
with the IC50 values reported in Figure 3 (Desantis et al., 2017). However, for some cHTC 
compounds, i.e., 32 and 54, that were highly active in PRAs, we did not observe a good correlation 
with their ability to disrupt the PA-PB1 interaction in vitro. To investigate whether these 
discrepancies could be in part due to the experimental conditions, we retested all cHTC compounds 
by a modified ELISA, wherein compounds were diluted in the same medium used for antiviral 
assays, i.e., serum-free DMEM instead of PBS. The PB1(1−15)-Tat peptide, a peptide interfering with 
the PA-PB1 interaction (Muratore et al., 2012a), was used as a positive control in this assay. In the 
modified assay, a moderate (3-fold) and a strong decrease (9-fold) in the IC50 values were obtained 
with compounds 31 and 54, respectively, when compared to the previous ELISA results (Figure 3). 
On the contrary, only negligible differences were observed between the two different assay 
conditions with compounds 21, 29, 32, and 37. Altogether, these data suggest that the medium 
composition used in the ELISA could affect the inhibitory activity of some compounds and that 
compounds 31 and 54 might be soluble in serum-free DMEM than in PBS. 
To demonstrate the specificity of the inhibitory activity on the PA-PB1 interaction, the 
compounds were similarly assayed in an ELISA which we previously used to characterize inhibitors 
of interactions between the human cytomegalovirus DNA polymerase subunits UL54 and UL44 
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(Loregian et al., 2003, Loregian and Coen, 2006). None of the compounds caused a dose-dependent 
reduction of UL54–UL44 binding up to a concentration of 200 μM (data not shown). 
Overall, the results from the ELISAs indicated that 21, 29, 31, and 54 were able to inhibit 
the interaction between PA and PB1 subunits in the low-micromolar concentration range (IC50 
values ranged from 5.2 µM to 15 µM; Figure 3C), whereas compound 32 and 37 showed only a 
weak PA-PB1 inhibitory activity in vitro (IC50 of 81 and 113 µM, respectively; Figure 3C). Thus, 
for the latter two compounds, 32 and 37, additional mechanisms of viral inhibition could exist.  
 
3.4 Selected cHTC compounds inhibit the activity of IAV polymerase in minireplicon assays  
To evaluate the ability of cHTC compounds to interfere with the IAV polymerase activity in a 
cellular context, a minireplicon assay was performed. HEK 293T cells were co-transfected with 
plasmids encoding PA, PB1, PB2, and NP proteins of IAV along with a plasmid containing the 
firefly luciferase reporter gene flanked by the noncoding regions of A/WSN/1933 segment 8, and 
treated with test compounds. In addition, a plasmid that constitutively expressed Renilla luciferase 
was also added to normalize variations in transfection efficiency. The firefly luciferase activity 
values were then normalized to the Renilla luciferase activity. RBV and favipiravir were included 
as positive controls. Each compound was also tested in parallel for cytotoxicity in HEK 293T cells 
by MTT assays to exclude that the observed inhibitions might be due to toxic side effects of the 
compounds. All tested compounds, except 37, were able to strongly inhibit the viral polymerase 
transcription activity at nontoxic concentrations and in a dose-dependent manner (Figure 4 and 
Table S3). In keeping with the results from PRAs, compounds 29, 31, 32, and 54 exerted inhibitory 
activity against IAV RdRP in the submicromolar range (EC50s from 0.27 µM to 1.0 µM), whereas 
21 inhibited RdRP activity at low-micromolar concentrations (EC50 of 2.8 µM). No/little inhibition 
was observed in minireplicon assay upon treatment with compound 37 up to 25 µM (Figure 4 and 
Table S3). Overall, also in this assay compound 54 was the most active, with an EC50 of 0.27 ± 0.04 
µM (Table S3). 
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3.5 Selected cHTC compounds have a high barrier to drug resistance in vitro 
To evaluate the propensity of this class of inhibitors to induce drug resistance, we tried to select in 
vitro influenza viruses resistant to the most promising compounds under drug selective pressure, 
following a procedure similar to that previously employed for other anti-influenza compounds, 
including PA-PB1 inhibitors (Molla et al., 2002; Shih et al., 2010; Ma et al., 2016; Hu et al., 2017; 
Zhang et al., 2018). The cHTC compounds that both inhibited the viral replication in PRAs with 
EC50 values ≤ 1 µM and disrupted specifically the PA-PB1 interaction in ELISA with IC50 values < 
20 µM were selected for these studies. Briefly, the IAV PR/8 strain was serially passaged at MOI 
0.001 in MDCK cells in the presence of increasing concentrations of 29, 31, and 54, or OST as a 
reference, starting from their EC50 values in PRA. Compound concentrations were serially two-fold 
increased at each passage (P) reaching concentrations 32-fold higher than the initial concentration 
and then kept constant until P10. After P10, drug-resistance selection was carried on only for the 
PA-PB1 inhibitors and the compound concentrations were maintained 32-fold higher than that 
applied at P0 for further ten passages. In the case of 29 and 31, these compound concentrations 
were between the EC75 and the EC90 values obtained in VYRA at the same MOI (Figure 2 and 
Table S2), thus enabling a strong selective pressure on virus replication while still allowing the 
virus to replicate at some extent in order to favor the emergence of compound-related mutations. A 
similar approach has been used for selecting viral variants resistant to other influenza virus 
polymerase inhibitors, such as favipiravir (Goldhill et al., 2018) and ribavirin (Cheung et al., 2014). 
The concentration applied for compound 54 at P11-P20 corresponded approximately to the EC75 
determined in VYRA, thus the selection studies were continued by performing ten additional 
passages (P21-P30) of the virus in the presence of 25 µM of compound 54. A summary of the 
compound concentrations employed during the whole selection process is reported in Table S4. To 
select possible cell culture–adapted variants and obtain mock–treated viruses, the same viral strain 
was passaged in parallel in the presence of DMSO. To monitor the emergence of cHTC 
compounds- or OST-resistant variants during the in vitro passages, the phenotypic susceptibility of 
passaged viruses to respective compounds was determined by PRA at P0 and then at selected 
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passages, starting from P3. As summarized in Table 2, the activity of compounds 29, 31, and 54 
remained unvaried over the whole in vitro selection process, as their EC50 values were constant 
from P0 to P20/P30. Moreover, the plaque sizes of the viral progeny harvested at P11 and P20/P30 
from cultures passaged in the presence of compounds 29, 31, and 54 were comparable to that of 
parental virus (P0) (Figure 5). 
On the contrary, the PR/8 virus sensitivity to OST rapidly changed during the virus passages 
in vitro (Table 2). Indeed, compared with P0 strain, OST-passaged viruses harvested at P5 and P7 
showed a slight reduction of susceptibility to OST (6- and 10-fold increase in EC50, respectively), 
and P9 and P10 viruses exhibited a strong shift in EC50 values, corresponding to a 130- and 390-
fold resistance to the drug, respectively (Table 2), according to previously reported data (Molla et 
al., 2002; McKimm-Breschkin et al., 2012). To discriminate if the OST-resistant variants obtained 
from P5, P7, P9, and P10 were induced by the drug selective pressure or were culture–adapted, OST 
was tested by PRA also against mock–passaged viruses harvested at the same passages. As 
expected, the susceptibilities to OST of mock–passaged viruses harvested at various passages 
(EC50s ranged from 0.007 µM to 0.013 µM, data not shown) did not substantially differ from that of 
parental virus (EC50 of 0.010 µM, Table 2), thus indicating that drug–resistance to OST was 
induced by the drug selective pressure.  
Taken together, these data demonstrated that compounds 29, 31, and 54 are considerably 
less prone than OST to develop drug resistance in vitro and overall suggest that dissociative 
inhibitors of the influenza virus polymerase could have a high barrier to the emergence of resistant 
viruses. 
 
4. Discussion 
A major limitation of the current available anti-influenza drugs is the emergence of drug-resistant 
viruses. This problem first emerged, and then became more pronounced, with the M2 channel 
inhibitors adamantanes, so that the use of this drug class is no longer recommended (Dong et al., 
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2015). However, there is also an alarming evidence of circulating influenza virus resistant to OST 
(Moscona, 2009; Li et al., 2015; Hussain et al., 2017). In this scenario, there is an urgent need to 
develop new anti-influenza drugs that act by new mechanisms of action. In this paper, we report the 
biological and biochemical characterization of cHTC compounds with potent anti-influenza 
activity, that act by disrupting the protein-protein interactions between the two subunits PA and 
PB1 of the viral RdRP. Moreover, we evaluated the barrier to drug resistance of selected cHTC 
compounds and found that they are impressively refractory to select drug-resistant viral variants 
under high-dose selective pressure. 
We previously reported that some cHTC compounds, i.e., 21, 29, 31, 32, 37, and 54, 
exhibited antiviral activity against IAV PR/8 with sub- or low-micromolar potency (Desantis et al., 
2017). We now demonstrated that they have potent, broad-spectrum activity against a panel of IAV 
and IBV strains, including clinical isolates. Importantly, these cHTC compounds fully retained 
activity against an OST-resistant clinical isolate of influenza virus, thus representing a potential 
alternative for developing rescue therapies to treat infections of influenza virus strains resistant to 
OST. Noteworthy, compound 54 efficiently inhibited in PRAs all tested influenza virus strains with 
EC50s ranging from 0.08 μM to 0.27 μM (Table 1), emerging as the most potent compound of the 
series and also of all PA−PB1 inhibitors developed so far by us. In addition, 54 exhibited an SI up 
to >3000 (Table 1), which is at least one order of magnitude higher than the values reported for all 
the other published PA−PB1 inhibitors. The potency and the SI of 54 were also comparable to those 
observed against IAV and IBV for the RdRP inhibitor favipiravir (EC50 values ranged from 0.083 to 
3.1 μM, reaching SIs > 2000; Furuta et al., 2002). The other two RdRP inhibitors currently 
approved or undergoing clinical phase III studies, baloxavir marboxil/S-033188 and pimodivir/VX-
787, were found to inhibit multiple IAV strains in CPE reduction assays at sub-nanomolar 
concentrations (Clark et al., 2014; Noshi et al., 2016). However, the range of antiviral activity of 
pimodivir is limited to IAV as this compound was found to be ineffective against IBV (Clark et al., 
2014).  
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In addition, a major advantage that the dissociative PA-PB1 inhibitors developed by us 
could have over the new inhibitors of PB2 and PA is a high barrier to the selection of resistant 
viruses. In fact, viruses resistant to baloxavir acid, the active form of the drug, were isolated after 6–
8 passages in vitro (Noshi et al., 2018), and amino acid substitutions in PB2 gene conferring 
reduced sensitivity to pimodivir were also reported to emerge in vitro, although no detailed analysis 
of resistance was conducted (Byrn et al., 2015). In contrast, we were not able to isolate viruses with 
reduced sensitivity to the cHTC compounds 29, 31, and 54. Indeed, IAV isolated after 20/30 serial 
passages in MDCK cells under increasing concentrations of these PA-PB1 inhibitors (up to 32/100-
fold their respective EC50s in PRA against the parental virus) completely retained the susceptibility 
to the compounds. On the other hand, influenza virus variants with reduced susceptibility to OST 
arose already after 5 viral passages, and highly OST-resistant viruses (i.e., displaying >100-fold 
increase in EC50 compared to the parent virus) were selected from P9.  
During the preparation of this manuscript, a study reporting the identification of a new PA-
PB1 inhibitor of influenza virus as well as the evaluation of the barrier to drug resistance of this 
compound was published (Zhang et al., 2018). In keeping with our findings, Zhang and coworkers 
showed that OST rapidly induced the selection of resistant viral variants, while no viruses with 
altered susceptibility to the PA-PB1 inhibitor were isolated. However, they stopped the selection 
process at P10 (Zhang et al., 2018), while we carried out a prolonged drug-resistance selection for a 
total of 20/30 viral passages. Altogether, our data and the results obtained by Zhang et al. suggest 
that drug resistance in vitro to dissociative inhibitors targeting the PA-PB1 interactions of influenza 
virus RdRP appears hard to develop, differently from what happens with the current anti-influenza 
drugs such as adamantanes and neuraminidase inhibitors and also with PA and PB2 enzymatic 
inhibitors approved or under clinical development (Hay et al., 1985; Molla et al., 2002; McKimm-
Breschkin et al., 2012; Byrn et al., 2015; Noshi et al., 2018). PA–PB1 interaction inhibitors might 
have a barrier to drug resistance even higher than that observed with the RdRP inhibitor favipiravir 
(Furuta et al., 2002; Baranovich et al., 2013; Daikoku et al., 2014). In the case of favipiravir, it has 
been observed that this drug induces lethal mutagenesis in the genome of influenza virus and many 
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other RNA viruses, causing the accumulation of transition mutations (Goldhill et al., 2019). For this 
reason, faviripavir-resistant viruses were considered unlikely to arise because this drug induces the 
generation of defective interfering viral particles and indeed until recently all the attempts to select 
escape mutants to this drug failed (Furuta et al., 2002; Baranovich et al., 2013; Daikoku et al., 
2014). Nonetheless, influenza virus variants resistant to favipiravir were recently isolated under 
drug selective pressure (Goldhill et al., 2018). Sequencing analysis of the isolated viral variants 
identified a mutation in the PB1 gene that conferred resistance to favipiravir and a secondary 
compensatory mutation in the PA gene to restore the viral fitness. In the case of PA-PB1 inhibitors, 
previous mutational studies showed that only very few amino acids substitutions are tolerated in the 
key residues of PA-PB1 interaction interface without a loss of binding and such mutations resulted 
in dramatic impairment of the viral polymerase activity as well as severe attenuation of the viral 
replication (Mänz et al., 2011). Most importantly, differently from what observed with favipiravir, 
no compensatory mutations able to restore even partially the viral fitness were identified (Mänz et 
al., 2011). In this paper, we also confirmed that compounds 21, 29, 31, and 54 act by interfering 
specifically with the binding of influenza virus polymerase PA-PB1 subunits, as these compounds 
were able to disrupt this interaction with IC50s in the low micromolar range, but were inactive 
against an unrelated protein-protein interaction (i.e., the human cytomegalovirus UL54-UL44 
interaction). Since the correct assembly of the RdRP complex is essential for its enzymatic activity, 
the inhibition of the PA-PB1 binding by compounds 21, 29, 31, and 54 also resulted in interference 
with the enzymatic activities of the IAV polymerase in a cellular context. Compound 54 was the 
most potent also in these assays. 
Given their different mechanism of action, we expect that specific PA-PB1 inhibitors, such 
as 21, 29, 31, and 54, could have a synergistic anti-influenza effect if combined not only with NA 
inhibitors but also with favipiravir, pimodivir, or baloxavir marboxil, and combinations studies will 
be the subject of our future work. This approach could not only achieve stronger antiviral activity, 
but also reduce the risk of development of drug-resistance to compounds with lower resistance 
barrier. In fact, as demonstrated by previous studies, synergistic antiviral effects were obtained by 
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combining favipiravir, pimodivir, or baloxavir marboxil with various NA inhibitors (Koszalka et al., 
2017; Kitano et al., 2017), but also by the combined use in vitro of two influenza virus RNA 
polymerase inhibitors, pimodivir and favipiravir (Bryn et al., 2015).  
In conclusion, these results demonstrate that our PA-PB1 inhibitors are potent and broad-
spectrum anti-influenza agents endowed with high barrier to drug-resistance in vitro. Overall, our 
findings support the further development of these cHTC compounds, either alone or in combination 
with other anti-influenza drugs, as promising candidates for the treatment of IAV and IBV 
infections. 
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FIGURE LEGENDS 
 
Fig. 1. Dose-dependent inhibition of IAV and IBV replication by cHTC compounds in PRA. 
(A) Dose-response curves of cHTC compounds, and RBV and OST as controls, on A/PR/8 and 
B/Lee viruses in MDCK cells. Data shown are the means ± SD of three experiments performed in 
duplicate. (B) The plaques of IAV PR/8 formed in the absence of compound (Mock) or in the 
presence of different concentrations of cHTC compounds of a representative experiment are shown.  
 
Fig. 2. Dose-dependent inhibition of IAV yield by cHTC compounds in VYRA. MDCK cells 
infected with IAV PR/8 at MOI = 0.001 were treated with different concentrations of cHTC 
compounds or RBV as a control. At 24 h p.i., virus progeny titers produced in the presence of test 
compounds were determined by titration on fresh MDCK cells by plaque assays. Data shown are 
the means ± SD of three experiments performed in duplicate. 
 
Fig. 3. Comparison of the inhibition of PA–PB1 interaction by cHTC compounds under two 
different ELISA conditions. (A) Test cHTC compounds or DMSO were dissolved in PBS buffer 
and added together with GST-PB1(1−25) into wells coated with 6His-PA(239−716). The PA-PB1 
binding was then detected by a GST-HRP antibody. Data shown represent the mean ± SD of at least 
three independent experiments in duplicate. (B) The PA−PB1 interaction assay was performed as in 
(A), but test compounds were dissolved in serum-free DMEM instead of PBS buffer. Data represent 
the averages ± SD of data obtained from at least three independent experiments in duplicate. (C) 
The IC50 values, corresponding to the compound concentrations that inhibit by 50% the PA-PB1 
interaction, in ELISA performed in PBS buffer (Desantis et al., 2017) or in serum-free DMEM are 
reported. Values represent the averages ± SD of data derived from at least three independent 
experiments in duplicate. 
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Fig. 4. Effects of cHTC compounds on the activity of IAV polymerase in cells. HEK 293T cells 
were co-transfected with plasmids expressing IAV PA, PB1, PB2, NP, or the firefly luciferase 
flanked by the noncoding genomic sequences of IAV in the presence of selected cHTC compounds, 
or RBV and favipiravir (FPV) as positive controls, or DMSO as a negative control. An additional 
plasmid, which constitutively expresses Renilla luciferase, was included to the transfection mixture. 
At 24 h post-transfection, luminescent signal of firefly luciferase was measured and normalized 
against that of Renilla luciferase. Values from samples treated with DMSO were set as 100%. All 
data shown represent the means ± SD of data obtained from at least two independent experiments in 
duplicate. 
 
Fig. 5. Plaque morphology of IAV PR/8 during serial passages with selected cHTC 
compounds. Panels show plaques from MDCK cells infected with PR/8 virus passaged in the 
absence of compound (Mock) or in the presence of compound 29, 31, or 54. After the indicated 
passage (P), fresh cell cultures were infected with supernatants containing the passaged virus and 
overlaid with Avicel cellulose containing TPCK-treated trypsin. After 48 h of incubation, cells were 
fixed with 4% formaldehyde and stained with 0.1% toluidine blue. 
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